New Launch6 Aug 2025, 03:04 pm
AstraZeneca Pharma India to Launch Eculizumab (Soliris) in India in August 2025
AI Summary
AstraZeneca Pharma India Limited has announced the launch of Eculizumab (Soliris) in India in August 2025. The drug is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) to inhibit complement — mediated thrombotic microangiopathy. This announcement comes after the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Eculizumab concentrate for solution for infusion 300 mg (10mg/ml) (SOLIRIS) in January 2025.
Key Highlights
- AstraZeneca Pharma India Limited will launch Eculizumab (Soliris) in August 2025 in India.
- Eculizumab (Soliris) is indicated for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) to inhibit complement — mediated thrombotic microangiopathy.
- The announcement follows the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Eculizumab concentrate for solution for infusion 300 mg (10mg/ml) (SOLIRIS) in January 2025.